EDAP International
This article was originally published in The Gray Sheet
Executive Summary
Acquires "certain assets" of Technomed International including exclusive U.S. distribution rights for Technomed's Sonolith lithotripter, Pulsolith laser lithotripter and Prostatron thermal therapy device. Earlier this year, EDAP's French parent company, EDAP International SA, "purchased the licenses, patents and manufacturing facility" of Technomed's parent in France (Technomed International SA), which had filed for bankruptcy in September 1993, according to EDAP. The company says Technomed will no longer be doing business in the U.S. A newly formed EDAP Technomed group will provide "continued sales, service and technical expertise" for Sonolith and Pulsolith customers. EDAP says it has completed 95% of a premarket approval application for the Prostatron for the treatment of benign prostrate hyperplasia and plans to submit the PMA in January 1995
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.